Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Conditions
Interventions
QPI-1007 Injection - 1.5 mg
QPI-1007 Injection - 3.0 mg
+1 more
Locations
85
United States
University of Arkansas Medical Center, Jones Eye Institute
Little Rock, Arkansas, United States
Loma Linda University Eye Institute
Loma Linda, California, United States
University of Southern California
Los Angeles, California, United States
NeuroEyeOrbit Institute
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
Unversity of California, Los Angeles (UCLA)
Pasadena, California, United States
Start Date
February 24, 2016
Primary Completion Date
July 1, 2019
Completion Date
July 1, 2019
Last Updated
July 20, 2020
Lead Sponsor
Quark Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions